Breakthrough in Spinal Cord Injury Treatment Using Human Organoids

Researchers at Northwestern University have made significant advancements in the treatment of spinal cord injuries, which often lead to paralysis due to poor regeneration of damaged nerve cells. Utilizing tiny organoids that mimic human spinal cord tissue, the team successfully demonstrated the potential for tissue repair and regeneration following injury. Biomedical engineer Samuel Stupp emphasized the importance of this research, stating, "After applying our therapy, the glial scar faded significantly... and we saw neurites growing, resembling the axon regeneration we saw in animals."

ScienceAlert

The researchers developed two distinct injury models in the human spinal cord organoids to evaluate their therapeutic approach. They created these organoids using induced pluripotent stem cells from an adult donor, allowing them to replicate much of the cellular architecture of a human spinal cord, including neurons and astrocytes. Once the organoids matured, they were subjected to injuries that simulated conditions leading to paralysis, such as scalpel cuts and compression injuries akin to those from car accidents.

ScienceAlert

Following injury, the organoids exhibited immediate nerve cell death and the formation of glial scars, mirroring the biological response seen in actual spinal cord injuries. The team then applied a treatment involving a material known as IKVAV-PA, which contains supramolecular therapeutic peptides designed to promote nerve cell regrowth. The treated organoids displayed significantly reduced inflammation and scarring, alongside enhanced nerve cell regrowth compared to control samples that did not receive the treatment.

ScienceAlert

While the research indicates promising results, Stupp cautioned that it is still likely years away from human testing. However, the consistency of results across both mouse and human tissue models provides a strong foundation for future therapeutic developments. Stupp noted, "One of the most exciting aspects of organoids is that we can use them to test new therapies in human tissue."

ScienceAlert

Despite the promising findings, some experts remain cautious about the transition from organoid studies to clinical applications. Concerns have been raised regarding the complexity of human spinal cord injuries and the potential differences in response between organoids and actual human patients.

ScienceAlert

The research has been published in *Nature Biomedical Engineering*, highlighting its significance in the field of regenerative medicine. The findings suggest that organoids could serve as a vital tool for testing new therapies before advancing to clinical trials.

ScienceAlert

• "We decided to develop two different injury models in a human spinal cord organoid and test our therapy to see if the results resembled what we previously saw in the animal model." — Samuel Stupp, Biomedical Engineer

ScienceAlert

• "If the molecules are sluggish and not as 'social,' they may never come into contact with the cells." — Samuel Stupp, Biomedical Engineer

ScienceAlert

• "We could distinguish between the astrocytes that are a part of normal tissue and the astrocytes in the glial scar." — Samuel Stupp, Biomedical Engineer

ScienceAlert

This research marks a significant step toward understanding and potentially treating spinal cord injuries, with the hope of improving outcomes for individuals affected by paralysis in the future.

ScienceAlert